{"id":"W2741746182","doi":"10.1016/j.hlc.2017.06.604","title":"Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, A Proprotein Convertase Subtilisin/Kexin type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data","year":2017,"lang":"en","type":"article","venue":"Heart Lung and Circulation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta","funders":"","keywords":"Alirocumab; PCSK9; Medicine; Evolocumab; Internal medicine; Acute coronary syndrome; Rosuvastatin; Statin; Interquartile range; Atorvastatin; Placebo; Gastroenterology; Apolipoprotein B; Myocardial infarction; Cholesterol; Lipoprotein; LDL receptor; Apolipoprotein A1; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001439728,0.000158737,0.000603842,0.00008185302,0.0001362362,0.00004334633,0.0001496645,0.00009697942,0.00001904872],"category_scores_gemma":[0.0004482467,0.0001125258,0.000102138,0.00006953693,0.0001197372,0.0003054006,0.00008481623,0.0001870727,0.000001293474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003383019,"about_ca_system_score_gemma":0.0001842995,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008578186,"about_ca_topic_score_gemma":0.0002191211,"domain_scores_codex":[0.9983301,0.000249358,0.0004483905,0.0003250869,0.0004676121,0.0001794679],"domain_scores_gemma":[0.9980605,0.0001415453,0.0002404419,0.001275039,0.0002174323,0.00006504394],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2927532,0.001515911,0.6377308,0.001066724,0.001912606,0.000488516,0.001989678,0.00007319879,0.03543535,0.0002437625,0.0003261812,0.026464],"study_design_scores_gemma":[0.03062436,0.001215906,0.9622273,0.0002002898,0.0001664855,0.0001872901,0.0001263523,0.004547652,0.0004737446,0.0000144692,0.00009773269,0.0001183615],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961768,0.0002436807,0.0001493768,0.001162418,0.000268579,0.001858319,0.0001216599,0.00001388074,0.000005239688],"genre_scores_gemma":[0.9984624,0.0001567498,0.0004686409,0.0001688338,0.00005441914,0.00001629475,0.0006415172,0.00001730627,0.00001387609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3244965,"threshold_uncertainty_score":0.9980237,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09928528665819061,"score_gpt":0.3648585546714165,"score_spread":0.2655732680132259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}